Gael Morrow

My main research interest lies in fibrinolysis and how clot structure alters the rate of lysis. I am currently working with Dr Nicola Curry and her team of clinicians at the Oxford Haemophilia and Thrombosis Centre at the Churchill Hospital. 

My work focuses on two different types of fibrinogen replacement administered to trauma patients.  Fibrinogen is the key pro-coagulant factor required for stable clot formation. Patients recruited to the Fibrinogen Early in Severe Trauma StudY (FEISTY) were given one of two treatments: cryoprecipitate or fibrinogen concentrate. My research investigates the differences in clot structure and strength between the two fibrinogens, and how this correlates with the clinical outcome.

The Intensive Care Study Of Coagulopathy 2 (ISOC-2) clinical trial recruited patients admitted to critical care that had abnormal clotting. Several interesting patient sub-groups arised, a group of particular interest is those with chronic liver disease.  A novel thrombin generation analyser will be used to investigate the role of the thrombomodulin : protein C pathway in predicting haemostatic balance and may be useful for assessment of disease progression in patients with liver disease. Ultimately, the goal is to provide better haemostatic testing that will allow clear indication to the clinician whether patients require plasma transfusion for minor procedures.